Search research articles
Contact Us
Filters
Showing results (701-710 of 711) with videos related to
Page
of 72
Sort By:
Oncogene
|
December 1, 2015
Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells
M O'Hayre, A Inoue, I Kufareva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
S Sugawara, S Oizumi, K Minato, et al.
ACS Omega
|
May 19, 2025
Valorization of Fish Waste Using Biochar and Crude Glycerin as Additives in Composting
Brenda K V Leite, Ana C A Orrico, Marco A P Orrico Junior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 25, 2015
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
K Kubota, H Sakai, N Katakami, et al.
Journal of Viral Hepatitis
|
August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
Y Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
N Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
T Oze, N Hiramatsu, T Yakushijin, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 29, 2009
Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead
H Du, T Matsushima, M Spyvee, et al.
Nature Communications
|
November 24, 2022
Breakup of the proton halo nucleus <sup>8</sup>B near barrier energies
L Yang, C J Lin, H Yamaguchi, et al.
Nature Communications
|
April 25, 2018
Evidence for prevalent Z = 6 magic number in neutron-rich carbon isotopes
D T Tran, H J Ong, G Hagen, et al.
Page
of 72
Search research articles
Search
Showing results (701-710 of 711) with videos related to
Sort By:
Page
of 72
Oncogene
|
December 1, 2015
Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the Gα13/RhoA axis in B cells
M O'Hayre, A Inoue, I Kufareva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 12, 2015
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
S Sugawara, S Oizumi, K Minato, et al.
ACS Omega
|
May 19, 2025
Valorization of Fish Waste Using Biochar and Crude Glycerin as Additives in Composting
Brenda K V Leite, Ana C A Orrico, Marco A P Orrico Junior, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 25, 2015
A randomized phase III trial of oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese patients with advanced non-small-cell lung cancer: TCOG0701 CATS trial
K Kubota, H Sakai, N Katakami, et al.
Journal of Viral Hepatitis
|
August 15, 2009
Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
Y Inoue, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
April 11, 2014
Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin
N Harada, N Hiramatsu, T Oze, et al.
Journal of Viral Hepatitis
|
June 26, 2009
Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
T Oze, N Hiramatsu, T Yakushijin, et al.
Bioorganic & Medicinal Chemistry Letters
|
September 29, 2009
Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead
H Du, T Matsushima, M Spyvee, et al.
Nature Communications
|
November 24, 2022
Breakup of the proton halo nucleus <sup>8</sup>B near barrier energies
L Yang, C J Lin, H Yamaguchi, et al.
Nature Communications
|
April 25, 2018
Evidence for prevalent Z = 6 magic number in neutron-rich carbon isotopes
D T Tran, H J Ong, G Hagen, et al.
Page
of 72